# US 2016/0354380 A1 · Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354380 A1
- Document ID: US20160354380A1
- Status: Published application
- Kind: A1
- Application number: 15/235,575
- Filed: 2016-08-12
- Published: 2016-12-08
- Earliest claimed: 2009-11-27
- Assignees: Boehringer Ingelheim International GmbH
- Applicants: Boehringer Ingelheim International GmbH
- Inventors: Klaus DUGI; Eva Ulrike GRAEFE-MODY; Michael MARK; Hans-Juergen WOERLE; Heike ZIMDAHL-GELLING
- Web page: https://patentgrep.com/patent/US20160354380A1

## CPC

- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 38/26: Glucagons
- A61K 38/28: Insulins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

Method for preventing, slowing the progression of, delaying or treating a metabolic disorder selected from the group consisting of type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, impaired fasting blood glucose, hyperglycemia, postprandial hyperglycemia, overweight, obesity and metabolic syndrome, or
for improving glycemic control and/or for reducing of fasting plasma glucose, of postprandial plasma glucose and/or of glycosylated hemoglobin HbA1c in a patient in need thereof, or for preventing, slowing, delaying or reversing progression from impaired glucose tolerance, impaired fasting blood glucose, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, or
for preventing, slowing the progression of, delaying or treating of a condition or disorder selected from the group consisting of complications of diabetes mellitus such as cataracts and micro- and macrovascular diseases, such as nephropathy, retinopathy, neuropathy, tissue ischaemia, diabetic foot, arteriosclerosis, myocardial infarction, accute coronary syndrome, unstable angina pectoris, stable angina pectoris, stroke, peripheral arterial occlusive disease, cardiomyopathy, heart failure, heart rhythm disorders and vascular restenosis, or
for reducing body weight or preventing an increase in body weight or facilitating a reduction in body weight, or
for preventing, slowing, delaying or treating the degeneration of pancreatic beta cells and/or the decline of the functionality of pancreatic beta cells and/or for improving and/or restoring the functionality of pancreatic beta cells and/or restoring the functionality of pancreatic insulin secretion, or
for preventing, slowing, delaying or treating diseases or conditions attributed to an abnormal accumulation of liver fat, or
for maintaining and/or improving the insulin sensitivity and/or for treating or preventing hyperinsulinemia and/or insulin resistance;
in a patient in need thereof, wherein the patient has one or more variations in one or more of the genes selected from TCF7L2 and GLP1R or in a patient who is of respective wild-type genotype,
said method comprising
testing whether the patient has one or more variations in one or more of the genes selected from TCF7L2 and GLP1R, and
administering a DPP-4 inhibitor selected from linagliptin, sitagliptin, vildagliptin, alogliptin, saxagliptin, teneligliptin and dutogliptin, and, optionally, a second antidiabetic agent selected from biguanides, thiazolidindiones, sulfonylureas, glinides, inhibitors of alpha-glucosidase, GLP-1 or GLP-1 analogues, and insulin or insulin analogues, and, optionally, a third antidiabetic agent selected from biguanides, thiazolidindiones, sulfonylureas, glinides, inhibitors of alpha-glucosidase, GLP-1 or GLP-1 analogues, and insulin or insulin analogues, to the patient, optionally in combination, including in alternation.

### Claim at position 3

15-21. (canceled)

### Claim 22

A method of using a pharmaceutical composition comprising
(a) DPP-4 inhibitor selected from linagliptin, sitagliptin, vildagliptin, alogliptin, saxagliptin, teneligliptin and dutogliptin, and, optionally,
(b) a second antidiabetic agent selected from the group G3 consisting of biguanides, thiazolidindiones, sulfonylureas, glinides, inhibitors of alpha-glucosidase, GLP-1 or GLP-1 analogues, and insulin or insulin analogues, and, optionally,
(c) a third antidiabetic agent being different from (b) selected from the group G3 consisting of biguanides, thiazolidindiones, sulfonylureas, glinides, inhibitors of alpha-glucosidase, GLP-1 or GLP-1 analogues, and insulin or insulin analogues,
or a pharmaceutically acceptable salt thereof,
for preventing, slowing the progression of, delaying or treating a metabolic disorder selected from the group consisting of type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, impaired fasting blood glucose, hyperglycemia, postprandial hyperglycemia, overweight, obesity, metabolic syndrome, insulin resistance, hyperlipidemia, hypercholesterolemia, dyslipidemia, hypertension, chronic systemic inflammation, retinopathy, neuropathy, nephropathy, atherosclerosis, endothelial dysfunction, non-alcoholic fatty liver disease (NAFLD) and osteoporosis; or
for improving glycemic control and/or for reducing of fasting plasma glucose, of postprandial plasma glucose and/or of glycosylated hemoglobin HbA1c; or
for preventing, slowing, delaying or reversing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus; or
for preventing, slowing the progression of, delaying or treating of a condition or disorder selected from the group consisting of complications of diabetes mellitus such as cataracts and micro- and macrovascular diseases, such as nephropathy, retinopathy, neuropathy, tissue ischaemia, diabetic foot, arteriosclerosis, myocardial infarction, accute coronary syndrome, unstable angina pectoris, stable angina pectoris, stroke, peripheral arterial occlusive disease, cardiomyopathy, heart failure, heart rhythm disorders and vascular restenosis; or
for reducing body weight or preventing an increase in body weight or facilitating a reduction in body weight; or
for preventing, slowing, delaying or treating the degeneration of pancreatic beta cells and/or the decline of the functionality of pancreatic beta cells and/or for improving and/or restoring the functionality of pancreatic beta cells and/or restoring the functionality of pancreatic insulin secretion; or
for preventing, slowing, delaying or treating diseases or conditions attributed to an abnormal accumulation of liver fat; or
for maintaining and/or improving the insulin sensitivity and/or for treating or preventing hyperinsulinemia and/or insulin resistance;
in a patient in need thereof,
wherein the patient has variation(s) in one or more genes associated with metabolic diseases,
the one or more of the genes selected from TCF7L2 and GLP1R, wherein said patient having a variation in the gene associated with TCF7L2 has one or more single nucleotide polymorphisms (SNPs) in the gene coding for TCF7L2 selected from rs7903146, rs12255372 and rs10885406,
or
in a patient being of
of wild-type genotype at rs7903146 of TCF7L2.

### Claim 23 (depends on 14)

Method according to claim 14 wherein the patient is an individual diagnosed of one or more of the conditions selected from the group consisting of overweight, obesity, visceral obesity and abdominal obesity.

### Claim 24 (depends on 14)

Method according to claim 14 wherein the patient is an individual who shows one, two or more of the following conditions:
(a) a fasting blood glucose or serum glucose concentration greater than 110 mg/dL, in particular greater than 125 mg/dL;
(b) a postprandial plasma glucose equal to or greater than 140 mg/dL;
(c) an HbA1c value equal to or greater than 6.5%, in particular equal to or greater than 7.0%.

### Claim 25 (depends on 14)

Method according to claim 14 wherein the patient is an individual wherein one, two, three or more of the following conditions are present:
(a) obesity, visceral obesity and/or abdominal obesity,
(b) triglyceride blood level ≧150 mg/dL,
(c) HDL-cholesterol blood level <40 mg/dL in female patients and <50 mg/dL in male patients,
(d) a systolic blood pressure ≧130 mm Hg and a diastolic blood pressure ≧85 mm Hg,
(e) a fasting blood glucose level ≧110 mg/dL.

### Claim 26 (depends on 14)

Method according to claim 14 wherein the patient has insufficient glycemic control despite diet and exercise or despite monotherapy with the second or the third antidiabetic agent.

### Claim 27 (depends on 14)

Method according to claim 14 wherein the patient has insufficient glycemic control despite diet and exercise or despite dual therapy with the second and the third antidiabetic agent.

### Claim 28 (depends on 14)

Method according to claim 14 wherein the patient has insufficient glycemic control despite diet and exercise or despite monotherapy with either the DPP-4 inhibitor or the second or third antidiabetic agent, or despite dual therapy with the second and the third antidiabetic agent.

### Claim 29 (depends on 14)

Method according to claim 14 wherein the patient has insufficient glycemic control despite diet and exercise or despite monotherapy with either the DPP-4 inhibitor, the second or the third antidiabetic agent, or despite combination therapy with two agents selected from the group of the DPP-4 inhibitor, the second and the third antidiabetic agent.

### Claim 30 (depends on 14)

Method according to claim 14 wherein the patient has one or more single nucleotide polymorphisms (SNPs) in the gene coding for TCF7L2, wherein at least one SNP is selected from rs7903146, rs12255372 and rs10885406.

### Claim 31 (depends on 14)

Method according to claim 14 wherein the patient is diagnosed for, has been diagnosed with or carries at least one T allele of SNP rs7903146 of TCF7L2.

### Claim 32 (depends on 14)

Method according to claim 14 wherein the patient is diagnosed for, has been diagnosed with or carries two T alleles of SNP rs7903146 of TCF7L2.

### Claim 33 (depends on 14)

Method according to claim 14 wherein the patient is diagnosed for, has been diagnosed with or carries one T allele of SNP rs7903146 of TCF7L2.

### Claim 34 (depends on 14)

Method according to claim 14 wherein the patient is diagnosed for, has been diagnosed with or carries wild-type genotype at rs7903146 of TCF7L2.

### Claim 35 (depends on 14)

Method according to claim 14 wherein the patient who is diagnosed for or carries two C alleles of SNP rs7903146 of TCF7L2.

### Claim 36

A method of using a pharmaceutical composition comprising
(a) DPP-4 inhibitor selected from linagliptin, sitagliptin, vildagliptin, alogliptin, saxagliptin, teneligliptin and dutogliptin, and, optionally,
(b) a second antidiabetic agent selected from the group G3 consisting of biguanides, thiazolidindiones, sulfonylureas, glinides, inhibitors of alpha-glucosidase, GLP-1 or GLP-1 analogues, and insulin or insulin analogues, and, optionally,
(c) a third antidiabetic agent being different from (b) selected from the group G3 consisting of biguanides, thiazolidindiones, sulfonylureas, glinides, inhibitors of alpha-glucosidase, GLP-1 or GLP-1 analogues, and insulin or insulin analogues,
or a pharmaceutically acceptable salt thereof,
for preventing, slowing the progression of, delaying or treating a metabolic disorder selected from the group consisting of type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, impaired fasting blood glucose, hyperglycemia, postprandial hyperglycemia, overweight, obesity and metabolic syndrome; or
for improving glycemic control and/or for reducing of fasting plasma glucose, of postprandial plasma glucose and/or of glycosylated hemoglobin HbA1c; or
for preventing, slowing, delaying or reversing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus; or
for preventing, slowing the progression of, delaying or treating of a condition or disorder selected from the group consisting of complications of diabetes mellitus such as cataracts and micro- and macrovascular diseases, such as nephropathy, retinopathy, neuropathy, tissue ischaemia, diabetic foot, arteriosclerosis, myocardial infarction, accute coronary syndrome, unstable angina pectoris, stable angina pectoris, stroke, peripheral arterial occlusive disease, cardiomyopathy, heart failure, heart rhythm disorders and vascular restenosis; or
for reducing body weight or preventing an increase in body weight or facilitating a reduction in body weight; or
for preventing, slowing, delaying or treating the degeneration of pancreatic beta cells and/or the decline of the functionality of pancreatic beta cells and/or for improving and/or restoring the functionality of pancreatic beta cells and/or restoring the functionality of pancreatic insulin secretion; or
for preventing, slowing, delaying or treating diseases or conditions attributed to an abnormal accumulation of liver fat; and/or
for maintaining and/or improving the insulin sensitivity and/or for treating or preventing hyperinsulinemia and/or insulin resistance;
in a patient in need thereof, said method comprising
(i) testing whether the patient is of any TCF7L2 risk genotype, wherein the patient has one or more single nucleotide polymorphisms (SNPs) in the gene coding for TCF7L2, wherein at least one SNP is selected from rs7903146, rs12255372 and rs10885406,
or testing whether the patient is of TCF7L2 rs7903146 wild genotype,
and, optionally,
(ii) administering to the patient the pharmaceutical composition.

### Claim 37 (depends on 14)

Method according to claim 14 wherein the DPP-4 inhibitor is linagliptin.

### Claim 38 (depends on 14)

Method according to claim 14 wherein the DPP-4 inhibitor is linagliptin, and the second antidiabetic agent is metformin or pioglitazone.

### Claim 39 (depends on 14)

Method according to claim 14 wherein the patient suffers from or has been diagnosed with type 2 diabetes mellitus.

### Claim 40 (depends on 36)

The method according to claim 36 wherein the patient is TCF7L2 rs7903146 CT or TT risk genotype.

### Claim 42 (depends on 36)

The method according to claim 36 wherein the patient is of TCF7L2 rs7903146 CC wild genotype.
